Reports Q4 revenue $99.01M, consensus $97.36M. “We ended the fiscal year with record revenue in the fourth quarter exceeding our guidance. By leveraging our technology, commercial execution and meeting the needs of our customers, we expanded our customer base and grew revenue 20% for the full fiscal year compared to the year prior,” said Emily Leproust, CEO and co-founder of Twist Bioscience (TWST). “As we enter fiscal 2026, we begin a new phase of growth for Twist, during which we expect to maintain gross margin above 50%, exit the fourth quarter of fiscal 2026 having achieved adjusted EBITDA breakeven and drive toward sustained and profitable growth.”
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST:
- Options Volatility and Implied Earnings Moves Today, November 14, 2025
- Cathie Wood Sells Tesla (TSLA) and SoFi Stocks, Makes a $34M Bet on This USDC Giant
- TWST Earnings this Week: How Will it Perform?
- Cathie Wood Sells Tesla (TSLA) Stock, and Buys This Stock after Q3 Beat
- Twist Bioscience initiated with an Overweight at Stephens